KBIO Insider Trading Activity and SEC Form 4 Filings
KBIO insider trading summary
No open-market insider purchases or sales of Kalobios Pharmaceuticals Inc (KBIO) have been reported on SEC Form 4 in the past 12 months.
Latest KBIO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 26, 2016 | Martin Shkreli | 10% Owner | Sell | $960K (309,723 @ $3.10) |
| Aug 25, 2016 | Martin Shkreli | 10% Owner | Sell | $5.9M (1,913,206 @ $3.10) |
| Dec 16, 2015 | Thomas Edward Fernandez | Director | Buy | $200K (6,821 @ $29.32) |
| Dec 16, 2015 | Michael Wayne Harrison | Director | Buy | $50K (1,705 @ $29.32) |
| Dec 16, 2015 | Anthion Partners II LLC | 10% Owner | Buy | $100K (3,410 @ $29.32) |
| Dec 16, 2015 | Marek Biestek | Director | Buy | $293K (10,000 @ $29.32) |
| Dec 16, 2015 | David Moradi | Director | Buy | $100K (3,410 @ $29.32) |
| Dec 16, 2015 | David Moradi | Director | Buy | $100K (3,410 @ $29.32) |
| Dec 16, 2015 | Anthion Partners II LLC | 10% Owner | Buy | $100K (3,410 @ $29.32) |
| Nov 24, 2015 | Martin Shkreli | Chief Executive Officer | Buy | $191K (5,000 @ $38.15) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.